CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval

Key Takeaways CHMP issued a positive opinion supporting EU approval of a 7.2 mg dose of Novo Nordisk's Wegovy.NVO's STEP UP study showed 20.7% average weight loss with 7.2 mg Wegovy versus 17.5% at 2.4 mg.About one-third of obesity patients on the 7.2 mg dose achieved at least 25% weight loss in the study.Novo Nordisk (NVO) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the EU approval of a higher dose of ...